EP4284408A4 - METHODS FOR PRODUCING SECRETOMES AND USES THEREOF - Google Patents

METHODS FOR PRODUCING SECRETOMES AND USES THEREOF Download PDF

Info

Publication number: EP4284408A4
Authority: EP; European Patent Office
Prior art keywords: secretomes; producing; methods; producing secretomes
Prior art date: 2021-01-27
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Pending

Application number

EP22746501.0A

Other languages

German (de)

French (fr)

Other versions

EP4284408A2 (en

Inventor

Jessie Silva PAINTER

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Immunis Inc

Original Assignee

Immunis Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2021-01-27

Filing date

2022-01-26

Publication date

2024-12-25

2022-01-26 Application filed by Immunis Inc filed Critical Immunis Inc

2023-12-06 Publication of EP4284408A2 publication Critical patent/EP4284408A2/en

2024-12-25 Publication of EP4284408A4 publication Critical patent/EP4284408A4/en

Status Pending legal-status Critical Current

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/48—Reproductive organs
- A61K35/54—Ovaries; Ova; Ovules; Embryos; Foetal cells; Germ cells
- A61K35/545—Embryonic stem cells; Pluripotent stem cells; Induced pluripotent stem cells; Uncharacterised stem cells
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- A61K38/1741—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals alpha-Glycoproteins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
- C07K14/4703—Inhibitors; Suppressors
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0603—Embryonic cells ; Embryoid bodies
- C12N5/0606—Pluripotent embryonic cells, e.g. embryonic stem cells [ES]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/30—Organic components
- C12N2500/34—Sugars
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/90—Serum-free medium, which may still contain naturally-sourced components
- C12N2500/95—Protein-free medium and culture conditions
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/115—Basic fibroblast growth factor (bFGF, FGF-2)
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/16—Activin; Inhibin; Mullerian inhibiting substance

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
General Health & Medical Sciences (AREA)
Zoology (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Gastroenterology & Hepatology (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Genetics & Genomics (AREA)
Immunology (AREA)
Developmental Biology & Embryology (AREA)
Epidemiology (AREA)
Biomedical Technology (AREA)
Biochemistry (AREA)
Cell Biology (AREA)
Reproductive Health (AREA)
Biotechnology (AREA)
Molecular Biology (AREA)
Marine Sciences & Fisheries (AREA)
Biophysics (AREA)
Toxicology (AREA)
Gynecology & Obstetrics (AREA)
Wood Science & Technology (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Neurology (AREA)
Orthopedic Medicine & Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Microbiology (AREA)
General Chemical & Material Sciences (AREA)
General Engineering & Computer Science (AREA)
Virology (AREA)
Hematology (AREA)

EP22746501.0A 2021-01-27 2022-01-26 METHODS FOR PRODUCING SECRETOMES AND USES THEREOF Pending EP4284408A4 (en)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
US202163142456P	2021-01-27	2021-01-27
US202163169203P	2021-03-31	2021-03-31
US202163177346P	2021-04-20	2021-04-20
PCT/US2022/013834 WO2022164854A2 (en)	2021-01-27	2022-01-26	Methods of preparation of secretomes, and uses thereof

Publications (2)

Publication Number	Publication Date
EP4284408A2 EP4284408A2 (en)	2023-12-06
EP4284408A4 true EP4284408A4 (en)	2024-12-25

Family

ID=82653820

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
EP22746501.0A Pending EP4284408A4 (en)	2021-01-27	2022-01-26	METHODS FOR PRODUCING SECRETOMES AND USES THEREOF

Country Status (7)

Country	Link
EP (1)	EP4284408A4 (en)
JP (1)	JP2024505886A (en)
KR (1)	KR20230167346A (en)
AU (1)	AU2022212832A1 (en)
CA (1)	CA3209584A1 (en)
IL (1)	IL304719A (en)
WO (1)	WO2022164854A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN116041477B (en) *	2022-10-13	2023-08-08	呈诺再生医学科技(北京)有限公司	Application of TDGF1 gene in preparing medicine for treating senility related diseases or reversing cell senility

Citations (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20120276215A1 (en) *	2011-04-26	2012-11-01	Riordan Neil H	Therapeutic Conditioned Media
US20200000882A1 (en) *	2018-06-27	2020-01-02	Juvena Therapeutics, Inc.	Heparin-associated polypeptides and uses thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU2002232394A1 (en) *	2000-10-27	2002-05-27	Wayne State University	Inhibition of alpha-2 hs glycoprotein (ahsg/fetuin) in obesity and insulin control of glucose homeostasis
WO2019046903A1 (en) *	2017-09-08	2019-03-14	Baker Heart and Diabetes Institute	A therapeutic method of increasing muscle mass in a subject

2022
- 2022-01-26 AU AU2022212832A patent/AU2022212832A1/en active Pending
- 2022-01-26 KR KR1020237029076A patent/KR20230167346A/en active Pending
- 2022-01-26 WO PCT/US2022/013834 patent/WO2022164854A2/en active Application Filing
- 2022-01-26 JP JP2023545273A patent/JP2024505886A/en active Pending
- 2022-01-26 EP EP22746501.0A patent/EP4284408A4/en active Pending
- 2022-01-26 CA CA3209584A patent/CA3209584A1/en active Pending
2023
- 2023-07-25 IL IL304719A patent/IL304719A/en unknown

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20120276215A1 (en) *	2011-04-26	2012-11-01	Riordan Neil H	Therapeutic Conditioned Media
US20200000882A1 (en) *	2018-06-27	2020-01-02	Juvena Therapeutics, Inc.	Heparin-associated polypeptides and uses thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
OZKAN H ET AL: "Fetuin-A as critical factor to maintain joint and muscle integrity after injury", OSTEOARTHRITIS AND CARTILAGE, ELSEVIER, AMSTERDAM, NL, vol. 28, 1 April 2020 (2020-04-01), XP086140684, ISSN: 1063-4584, [retrieved on 20200420], DOI: 10.1016/J.JOCA.2020.02.310 *

Also Published As

Publication number	Publication date
KR20230167346A (en)	2023-12-08
CA3209584A1 (en)	2022-08-04
WO2022164854A3 (en)	2022-09-15
WO2022164854A2 (en)	2022-08-04
JP2024505886A (en)	2024-02-08
EP4284408A2 (en)	2023-12-06
AU2022212832A1 (en)	2023-09-07
IL304719A (en)	2023-09-01

Publication	Publication Date	Title
EP4206220C0 (en)	2024-10-02	PROINSULINGLARGIN AND METHOD FOR PRODUCING INSULINGLARGIN THEREFROM
EP4009778A4 (en)	2023-09-27	METHOD AND COMPOSITIONS FOR PRODUCING ECTOMYCORRHIZA MYcelium AND METHOD FOR USE THEREOF
EP4330418C0 (en)	2024-12-04	USE AND METHOD FOR THE PRODUCTION OF MONO-RHAMNOLIPIDS
EP4026856A4 (en)	2023-09-27	METHOD FOR PRODUCING PERFLUOREL ELASTOMER AND COMPOSITION
EP4023422A4 (en)	2024-03-06	METHOD FOR PRODUCING STRUCTURE AND STRUCTURE
EP4032850A4 (en)	2023-10-04	QUANTUM POINT AND METHOD FOR PRODUCING THEREOF
EP4061352A4 (en)	2024-02-28	COMPOUNDS AND METHODS FOR PRODUCING S1P1-MODULATING COMPOUNDS
EP4046767A4 (en)	2023-11-01	EXTRUDER AND METHOD FOR PRODUCING STRANDS
EP4359420A4 (en)	2025-07-16	25-HYDROXY-CHOLEST-5-EN-3-SULFATCHOLINE AND PROCESS FOR THE PREPARATION AND USES THEREOF
EP4330362C0 (en)	2024-10-23	USE AND METHOD FOR THE PRODUCTION OF MONO-RHAMNOLIPIDS
EP4360624A4 (en)	2025-06-25	Lipid DNANOparticles and methods for producing the same
EP4252540A4 (en)	2024-10-30	TISSUE-SHAPED PROTEIN COMPONENT AND METHOD FOR THE PRODUCTION THEREOF
EP4269691A4 (en)	2025-06-25	Pulp-molded article and method for producing the same
EP4217503A4 (en)	2024-12-11	METHOD FOR THE PRODUCTION OF SEMAGLUTIDE AND SEMAPEPTIDE
EP4155264A4 (en)	2024-10-09	COMPOSITION AND METHOD FOR THE PRODUCTION THEREOF
EP4282523A4 (en)	2024-10-09	DENITRITION CATALYST AND METHOD FOR PRODUCING THE SAME
EP4149885C0 (en)	2025-04-02	PROCESS FOR PRODUCING AEROGELS AND AEROGELS OBTAINABLE THEREBY
EP4284408A4 (en)	2024-12-25	METHODS FOR PRODUCING SECRETOMES AND USES THEREOF
EP4060022A4 (en)	2024-02-21	METHOD FOR PRODUCING ALMOND ORGANOIDS AND USE THEREOF
EP3814126C0 (en)	2024-12-25	METHOD FOR PRODUCING COMPOSITES AND ARRANGEMENT FOR PRODUCING COMPOSITES
EP4425527A4 (en)	2025-01-22	SECURITY AND METHOD FOR PRODUCING SAME
EP4319975C0 (en)	2025-02-19	Panel and method for producing the same
EP4253645A4 (en)	2025-03-26	Artificial leather and method for producing the same
EP4157997A4 (en)	2024-12-11	INDUCED REGULATORY T CELLS, METHODS OF PRODUCING THEM AND USES THEREOF
EP4129992A4 (en)	2024-04-10	FLUORESCENT RESIN AND METHOD FOR PRODUCING SAME

Legal Events

Date	Code	Title	Description
2022-08-05	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE
2023-11-03	PUAI	Public reference made under article 153(3) epc to a published international application that has entered the european phase	Free format text: ORIGINAL CODE: 0009012
2023-11-03	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE
2023-12-06	17P	Request for examination filed	Effective date: 20230821
2023-12-06	AK	Designated contracting states	Kind code of ref document: A2 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
2024-05-01	DAV	Request for validation of the european patent (deleted)
2024-05-01	DAX	Request for extension of the european patent (deleted)
2024-09-20	REG	Reference to a national code	Ref country code: HK Ref legal event code: DE Ref document number: 40106732 Country of ref document: HK
2024-12-25	A4	Supplementary search report drawn up and despatched	Effective date: 20241122
2024-12-25	RIC1	Information provided on ipc code assigned before grant	Ipc: C12N 5/074 20100101ALI20241118BHEP Ipc: A61P 21/00 20060101ALI20241118BHEP Ipc: A61K 35/28 20150101ALI20241118BHEP Ipc: A61K 38/17 20060101AFI20241118BHEP